The short answer: what kind of cartilage damage ChondroFiller targets

ChondroFiller is suited to a specific, well-defined category of joint damage — a discrete area of cartilage loss rather than widespread wear across the joint. That distinction matters from the outset, because this is not a treatment for general osteoarthritis or whole-joint degeneration.

Delivered as an ultrasound-guided outpatient injection, ChondroFiller places an injectable collagen scaffold directly into the damaged area during an in-clinic appointment — no theatre admission or surgical incision is involved. Once in position, the scaffold works by recruiting the patient's own progenitor cells into the repair site, a process known as acellular matrix-induced chondrogenesis. In plain terms, it supports the body's own repair processes rather than replacing lost tissue with an artificial substitute.

The patients most likely to benefit sit at a particular point on the treatment pathway: beyond what physiotherapy and pain management alone can achieve, but not yet at the threshold where total joint replacement becomes the appropriate next step. Within that window, the specific anatomy of the defect — its size, depth, location, and the condition of the surrounding cartilage — determines whether ChondroFiller is the right fit.

The sections below set out each of those criteria in detail.

Defect grade and size: the anatomical thresholds

Cartilage grading scales give clinicians a shared language for describing damage depth — and for a patient reading a consultant letter or MRI report, understanding where Grade III and Grade IV sit can clarify why the threshold matters.

Grade III means the cartilage has worn through more than half its depth but a thin layer still covers the underlying bone. Grade IV means that cover is gone: the bone beneath is exposed or nearly so. Both grades represent serious focal damage, yet the joint around the defect retains enough structural integrity for a scaffold-based repair to work. Earlier grades (I and II) involve surface fraying or shallower loss and are generally managed differently; by contrast, the diffuse, bone-on-bone destruction of end-stage osteoarthritis lies beyond what ChondroFiller is designed to address.

Equally important is the shape of the damage. A qualifying defect is focal and contained — more like a pothole in an otherwise serviceable road than general surface erosion across the whole carriageway. The cartilage margins surrounding the defect must be healthy and stable, because the collagen scaffold gel anchors to that rim as it fills the void and begins recruiting the patient's own cells.

On area, the consistently cited upper limit in clinical practice is approximately 6 cm². Lesions under 3 cm² tend to show the most predictable filling and biological integration; larger defects up to that 6 cm² ceiling remain within the treatable range, though outcomes become less uniform. It is worth noting that the 6 cm² figure reflects a practical clinical guideline rather than a threshold confirmed by large prospective trials — the evidence base, while supportive, is still maturing.

What the surrounding joint must look like

Even a defect that meets the grade and size criteria will not respond well if the broader joint environment cannot support scaffold integration. Three factors determine that environment — alignment, stability, and overall joint health — and each is assessed by a specialist rather than estimated by the patient from symptoms alone.

Alignment must be within approximately 5 degrees of neutral. When a limb carries more load through one compartment than the other, mechanical stress concentrates on the repair site before the scaffold has had time to consolidate. That uneven loading undermines the repair process at its foundation.

Ligament stability, particularly of the ACL in the knee, is a parallel requirement. A lax or ruptured ACL generates abnormal shear forces across the joint — the collagen scaffold cannot integrate predictably in a mechanically unstable environment. Reconstruction may be performed concurrently or prior to the injection, depending on the clinical picture.

Overall OA staging is assessed using the Kellgren-Lawrence (KL) scale. KL grades I–III, where some joint space is preserved, represent the working inclusion range. KL grade IV — with severe joint space narrowing and extensive degeneration — sits outside the indication. In a hip arthroscopy cohort, patients who already had Tönnis grade 2–3 osteoarthritis achieved poor outcomes despite focal defect treatment, making advanced joint degeneration the strongest published predictor of treatment failure, regardless of defect size.

Active joint infection and inflammatory arthropathies such as rheumatoid or psoriatic arthritis are firm contraindications: both alter the joint environment in ways that prevent normal cell recruitment into the scaffold.

Patient profile: age, activity level, and cause of damage

Beyond the anatomical criteria already described, the human profile of someone assessed for ChondroFiller spans a broader range than many patients expect.

The aetiologies most commonly encountered are trauma-related: a focal chondral lesion following a sports injury, damage associated with osteochondritis dissecans (OCD), or cartilage loss arising after a meniscal or ligament injury. These present as discrete, contained defects in an otherwise younger, mechanically sound joint — the circumstances in which scaffold-based repair is most predictable. A 2024 knee study from Bulgaria enrolled 17 patients with a mean age of 31, reporting significant Lysholm and IKDC score improvements at 3, 6, and 12 months, confirming that younger adults with focal traumatic or early degenerative lesions are established candidates.

Active patients aged approximately 40–65 at a healthy body weight are reported in clinical practice to achieve the best regenerative outcomes. This reflects adequate host-cell migration capacity rather than a formally published age cut-off; no upper age limit is defined in the device criteria.

Limited focal degeneration is also within scope where progenitor cell recruitment remains viable — this is distinct from diffuse osteoarthritis, which sits outside the indication.

Body weight is a practical consideration: excess load on the scaffold before it has stabilised can impair integration, and specialists typically factor BMI into the overall assessment alongside imaging findings.

Who is not a candidate

Several conditions place a patient outside the indication, and recognising them early sets realistic expectations before any specialist consultation.

Diffuse or end-stage osteoarthritis is the principal exclusion. Because ChondroFiller is designed to fill a contained focal lesion, widespread cartilage loss across the joint surface is a fundamentally different clinical problem — a focal scaffold cannot address it. Patients in this category are generally further along the pathway, closer to joint replacement than injection-based repair.

Osteochondral lesions, where substantial bone loss underlies the cartilage damage, warrant specialist review rather than an automatic exclusion. ChondroFiller's primary target is the chondral layer; where the subchondral bone is extensively involved, the published evidence is more limited and a different strategy may be more appropriate.

Allergy to collagen or animal-derived proteins is an absolute contraindication. The scaffold is a type I collagen hydrogel of biological origin, making this a non-negotiable safety check before proceeding.

Pregnancy is excluded on precautionary grounds.

Inflammatory arthropathies and active joint infection — discussed in the context of joint-environment requirements above — are firm contraindications for the same underlying reason: both disrupt the local biology that the scaffold depends on.

If any of these factors apply, a specialist assessment can identify which alternative pathways better match the individual's joint condition and clinical history.

How candidacy is assessed — and finding the right specialist

Before any treatment decision can be made, imaging is needed to characterise the defect precisely. MRI is the non-negotiable starting point — it confirms defect geometry, grade, and the focal-versus-diffuse pattern that distinguishes eligible candidates from those with more generalised joint degeneration. Clinical examination alone cannot establish these distinctions reliably.

Functional scoring tools give the assessment a quantitative baseline alongside imaging. The VAS records pain intensity on a simple numerical scale; WOMAC captures pain, stiffness, and physical function together; IKDC scores knee-specific function and activity level; and the Lysholm scale evaluates symptoms including locking, instability, and swelling. These same measures serve as benchmarks if treatment proceeds — the published knee studies tracked IKDC and Lysholm at 3, 6, and 12 months as their primary indices of progress.

Candidacy is ultimately a shared clinical decision. The same defect in two patients may lead to different recommendations once activity goals, occupation, alignment, and overall joint health are weighed alongside the imaging findings. No single threshold is decisive in isolation; a specialist integrates all of these factors in reaching a recommendation.

Specialists offering ChondroFiller injection across the UK can be identified through Search MSK, which allows filtering by region and specialty.